Author name: Paul Patrick

cdc-vaccine-panel-realizes-again-it-has-no-idea-what-it’s-doing,-delays-big-vote

CDC vaccine panel realizes again it has no idea what it’s doing, delays big vote


Today’s meeting was chaotic and included garbage anti-vaccine presentations.

Dr. Robert Malone speaks during a meeting of the CDC Advisory Committee on Immunization Practices (ACIP) at CDC Headquarters on December 4, 2025 in Atlanta, Georgia. Credit: Getty | Elijah Nouvelage

The panel of federal vaccine advisors hand-selected by anti-vaccine Health Secretary Robert F. Kennedy Jr. has once again punted on whether to strip recommendations for hepatitis B vaccinations for newborns—a move it tried to make in September before realizing it didn’t know what it was doing. The decision to delay the vote today came abruptly this afternoon when the panel realized it still does not understand the topic or what it was voting on.

Prior to today’s 6–3 vote to delay a decision, there was a swirl of confusion over the wording of what a new recommendation would be. Panel members had gotten three different versions of the proposed recommendation in the 72 hours prior to the meeting, one panelist said. And the meeting’s data presentations this morning offered no clarity on the subject—they were delivered entirely by anti-vaccine activists who have no subject matter expertise and who made a dizzying amount of false and absurd claims.

“Completely inappropriate”

Overall, the meeting was disorganized and farcical. Kennedy’s panel has abandoned the evidence-based framework for setting vaccine policy in favor of airing unvetted presentations with misrepresentations, conspiracy theories, and cherry-picked studies. At times, there were tense exchanges, chaos, confusion, and misunderstandings.

Still, the discussion was watched closely by the medical and health community, which expects that the panel—composed of Kennedy allies who espouse anti-vaccine views—will strip the recommendation for a hepatitis B vaccine birth dose. Decisions by the committee, the Advisory Committee on Immunization Practices (ACIP) in the Centers for Disease Control and Prevention, have historically set national vaccine policy. Health insurance programs are required to cover, at no cost, vaccinations recommended by the ACIP. So rescinding a recommendation means Americans could lose coverage.

Medical and public health experts consider the birth-dose vaccination to be critical for protecting all infants from contracting the highly infectious virus that, when acquired early in life from their mother or anyone else, almost always causes chronic infections that lead to liver disease, cancer, and early death. There is no data suggesting harms from the newborn dose, nor any safety data suggesting that delaying the first dose by a month or two, as ACIP is considering, would be safer or better in any way. But studies do indicate that such a delay would lead to more hepatitis B infections in babies

These points were hard to find in today’s presentations. Abandoning standard protocol, the meeting did not include any presentations or data reviews led by CDC scientists or subject matter experts. Kennedy has also barred medical and health expert liaisons—such as the American Medical Association, the Infectious Disease Society of America, and the American Academy of Pediatrics—from participating in the ACIP working groups, which compile data and set language for proposed vaccine recommendations.

Anti-vaccine presentations

Instead, today, ACIP heard only from anti-vaccine activists. The first was Cynthia Nevison, a climate researcher and anti-vaccine activist with ties to Children’s Health Defense, Kennedy’s anti-vaccine organization. She was also a board member of an advocacy group called Safe Minds, which promotes a false link between autism and vaccines, specifically the mercury-containing vaccine preservative thimerosal, which was removed from routine childhood vaccines in the early 2000s. (Safe Minds stands for Sensible Action For Ending Mercury-Induced Neurological Disorders.) According to her academic research profile at the University of Colorado Boulder, her expertise is in “global biogeochemical cycles of carbon and nitrogen and their impact on atmospheric trace gases.”

Far from that topic, Nevison gave a presentation downplaying the transmission of hepatitis B and the benefits of vaccines. She falsely claimed that the dramatic decline in hepatitis B infections that followed vaccination efforts was not actually due to the vaccination efforts—despite irrefutable evidence that it was. And she followed that up with her own unvetted modeling claiming that CDC scientists overestimate the risk of transmission. She ended by presenting a few studies showing declines in blood antibody levels after initial vaccination, which she claimed suggests that the hepatitis B vaccine does not offer lifelong protection, an incorrect takeaway based on her lack of expertise.

The author of one of the studies just happened to be present at today’s meeting. Pediatrician Amy Middleman, who is an ACIP liaison representing the Society for Adolescent Health and Medicine (SAHM) and a professor at Case Western Reserve University School of Medicine, was the first author on a key study Nevison referenced. Middleman was quick to point out that Nevison had completely misunderstood the study, which actually showed that cell-based immune protection from the vaccine offers robust lifelong protection, even after initial antibody levels decline (called an anamnestic response).

“This is where a really experienced understanding of immunization comes into play,” Middleman said. “The entire point of our study is that for most vaccines, the anamnestic response is really their superpower. So this study showed that memory cells exist such that when they see something that looks like the hepatitis B disease, they actually attack. The presence of a robust and anamnestic response, regardless of circulating antibody years later, shows true protection.”

The next presentation was from Mark Blaxill, an anti-vaccine activist installed at the CDC in September. Blaxill gave a presentation on hepatitis B vaccine safety, despite having no background in medicine or science. He previously worked as an executive for a technology investment firm and, like Nevison, also worked for Safe Minds, where he was vice president. Blaxill has written books and many articles falsely claiming that vaccines cause a variety of harms in children. In 2004, when an Institute of Medicine analysis concluded that there were no convincing links between vaccines and autism, Blaxill publicly protested the result.

In his presentation, he attacked the quality of safety data in past hepatitis B studies. Though he stopped short of suggesting any specific harms from the vaccine, he aired unsubstantiated possibilities popular with anti-vaccine activists. He also noted a study finding that some babies had fatigue and irritability after vaccination, which he bizarrely suggested was a sign of encephalitis (inflammation of the brain).

Real-time feedback

Cody Meissner, a pediatrician and voting member of ACIP who is the most qualified and experienced member of the panel, quickly called out the suggestion as ridiculous. “That is absolutely not encephalitis,” Meissner said with frustration in his voice. “That’s not a statement that a physician would make. [Those symptoms] are not related to encephalitis, and you can’t say that.”

As in previous meetings, Jason Goldman, the ACIP liaison representing the American College of Physicians, gave the most biting response to the meeting overall, saying:

Once again, this committee fails to use the evidence to recommend framework and shows absolutely no understanding of the process or the gravity of the moment of the recommendations that you make. We need to look at all the evidence and data and not cherry-pick them… This meeting is completely inappropriate for an administration that wants to avoid fraud, waste, and abuse. You are wasting taxpayer dollars by not having scientific, rigorous discussion on issues that truly matter. The best thing you can do is adjourn the meeting and discuss vaccine issues that actually need to be taken up…  As physicians, your ethical obligation is primum non nocere, first do no harm, and you are failing in that by promoting this anti-vaccine agenda without the data and evidence necessary to make those informed decisions.

The panel will reconvene tomorrow for an all-day meeting in which the members will consider a vote on the hepatitis B vaccine for a third time. The meeting will also host other anti-vaccine presentations attacking the childhood vaccine schedule in its entirety.

Photo of Beth Mole

Beth is Ars Technica’s Senior Health Reporter. Beth has a Ph.D. in microbiology from the University of North Carolina at Chapel Hill and attended the Science Communication program at the University of California, Santa Cruz. She specializes in covering infectious diseases, public health, and microbes.

CDC vaccine panel realizes again it has no idea what it’s doing, delays big vote Read More »

oneplus-15-finally-gets-fcc-clearance-after-government-shutdown-delay—preorders-live

OnePlus 15 finally gets FCC clearance after government shutdown delay—preorders live

In the Ars review of the OnePlus 15, we were floored by the phone’s incredible battery life and super-fast charging. The device’s other performance characteristics are similarly speedy, as is the OnePlus way. However, the phone is also less interesting visually compared to its predecessor, and the camera is a step down compared to the OnePlus 13, which launched not even a year ago.

OnePlus 15 side

There is somehow a 7,300 mAh battery in there.

Credit: Ryan Whitwam

There is somehow a 7,300 mAh battery in there. Credit: Ryan Whitwam

If you’re convinced, you can get in line now. Just don’t expect the phone to show up immediately. OnePlus estimates that the first units will arrive just days before the end of 2025. On the plus side, anyone who preorders now will get a free gift. You can currently choose between the OnePlus Buds Pro 3, an AIRVOOC 50 W wireless charger (fully supported on the OnePlus 15), or one of several phone cases.

While OnePlus does make great phone cases, the earbuds are the highest value option at $180 MSRP. That’s not bad for a preorder bonus! However, OnePlus notes the freebies are only available while supplies last. You can wait for the phone to appear at other retailers, and it will eventually go on sale, but you won’t get the free earbuds.

OnePlus 15 finally gets FCC clearance after government shutdown delay—preorders live Read More »

in-1995,-a-netscape-employee-wrote-a-hack-in-10-days-that-now-runs-the-internet

In 1995, a Netscape employee wrote a hack in 10 days that now runs the Internet

Thirty years ago today, Netscape Communications and Sun Microsystems issued a joint press release announcing JavaScript, an object scripting language designed for creating interactive web applications. The language emerged from a frantic 10-day sprint at pioneering browser company Netscape, where engineer Brendan Eich hacked together a working internal prototype during May 1995.

While the JavaScript language didn’t ship publicly until that September and didn’t reach a 1.0 release until March 1996, the descendants of Eich’s initial 10-day hack now run on approximately 98.9 percent of all websites with client-side code, making JavaScript the dominant programming language of the web. It’s wildly popular; beyond the browser, JavaScript powers server backends, mobile apps, desktop software, and even some embedded systems. According to several surveys, JavaScript consistently ranks among the most widely used programming languages in the world.

In crafting JavaScript, Netscape wanted a scripting language that could make webpages interactive, something lightweight that would appeal to web designers and non-professional programmers. Eich drew from several influences: The syntax looked like a trendy new programming language called Java to satisfy Netscape management, but its guts borrowed concepts from Scheme, a language Eich admired, and Self, which contributed JavaScript’s prototype-based object model.

A screenshot of the Netscape Navigator 2.0 interface.

A screenshot of the Netscape Navigator 2.0 interface. Credit: Benj Edwards

The JavaScript partnership secured endorsements from 28 major tech companies, but amusingly, the December 1995 announcement now reads like a tech industry epitaph. The endorsing companies included Digital Equipment Corporation (absorbed by Compaq, then HP), Silicon Graphics (bankrupt), and Netscape itself (bought by AOL, dismantled). Sun Microsystems, co-creator of JavaScript and owner of Java, was acquired by Oracle in 2010. JavaScript outlived them all.

What’s in a name?

The 10-day creation story has become programming folklore, but even with that kernel of truth we mentioned, it tends to oversimplify the timeline. Eich’s sprint produced a working demo, not a finished language, and over the next year, Netscape continued tweaking the design. The rushed development left JavaScript with quirks and inconsistencies that developers still complain about today. So many changes were coming down the pipeline, in fact, that it began to annoy one of the industry’s most prominent figures at the time.

In 1995, a Netscape employee wrote a hack in 10 days that now runs the Internet Read More »

republicans-drop-trump-ordered-block-on-state-ai-laws-from-defense-bill

Republicans drop Trump-ordered block on state AI laws from defense bill


“A silly way to think about risk”

“Widespread and powerful movement” keeps Trump from blocking state AI laws.

A Donald Trump-backed push has failed to wedge a federal measure that would block states from passing AI laws for a decade into the National Defense Authorization Act (NDAA).

House Majority Leader Steve Scalise (R-La.) told reporters Tuesday that a sect of Republicans is now “looking at other places” to potentially pass the measure. Other Republicans opposed including the AI preemption in the defense bill, The Hill reported, joining critics who see value in allowing states to quickly regulate AI risks as they arise.

For months, Trump has pressured the Republican-led Congress to block state AI laws that the president claims could bog down innovation as AI firms waste time and resources complying with a patchwork of state laws. But Republicans have continually failed to unite behind Trump’s command, first voting against including a similar measure in the “Big Beautiful” budget bill and then this week failing to negotiate a solution to pass the NDAA measure.

Among Republican lawmakers pushing back this week were Rep. Marjorie Taylor Greene (R-Ga.), Arkansas Gov. Sarah Huckabee Sanders, and Florida Gov. Ron DeSantis, The Hill reported.

According to Scalise, the effort to block state AI laws is not over, but Republicans caved to backlash over including it in the defense bill, ultimately deciding that the NDAA “wasn’t the best place” for the measure “to fit.” Republicans will continue “looking at other places” to advance the measure, Scalise said, emphasizing that “interest” remains high, because “you know, you’ve seen the president talk about it.”

“We MUST have one Federal Standard instead of a patchwork of 50 State Regulatory Regimes,” Trump wrote on Truth Social last month. “If we don’t, then China will easily catch us in the AI race. Put it in the NDAA, or pass a separate Bill, and nobody will ever be able to compete with America.”

If Congress bombs the assignment to find another way to pass the measure, Trump will likely release an executive order to enforce the policy. Republicans in Congress had dissuaded Trump from releasing a draft of that order, requesting time to find legislation where they believed an AI moratorium could pass.

“Widespread” movement blocked Trump’s demand

Celebrating the removal of the measure from the NDAA, a bipartisan group that lobbies for AI safety laws, Americans for Responsible Innovation (ARI), noted that Republicans didn’t just face pressure from members of their own party.

“The controversial proposal had faced backlash from a nationwide, bipartisan coalition of state lawmakers, parents, faith leaders, unions, whistleblowers, and other public advocates,” an ARI press release said.

This “widespread and powerful” movement “clapped back” at Republicans’ latest “rushed attempt to sneak preemption through Congress,” Brad Carson, ARI’s president, said, because “Americans want safeguards that protect kids, workers, and families, not a rules-free zone for Big Tech.”

Senate Majority Leader John Thune (R-SD) called the measure “controversial,” The Hill reported, suggesting that a compromise that the White House is currently working on would potentially preserve some of states’ rights to regulate some areas of AI since “you know, both sides are kind of dug in.”

$150 million war over states’ rights to regulate AI

Perhaps the clearest sign that both sides “are kind of dug in” is a $150 million AI lobbying war that Forbes profiled last month.

ARI is a dominant group on one side of this war, using funding from “safety-focused” and “effective altruism-aligned” donor networks to support state AI laws that ARI expects can be passed much faster than federal regulations to combat emerging risks.

The major player on the other side, Forbes reported, is Leading the Future (LTF), which is “backed by some of Silicon Valley’s largest investors” who want to block state laws and prefer a federal framework for AI regulation.

Top priorities for ARI and like-minded groups include protecting kids from dangerous AI models, preventing AI from supercharging crime, protecting against national security threats, and getting ahead of “long-term frontier-model risks,” Forbes reported.

But while some Republicans have pushed for compromises that protect states’ rights to pass laws shielding kids or preventing fraud, Trump’s opposition to AI safety laws like New York’s “RAISE Act” seems unlikely to wane as the White House mulls weakening the federal preemption.

Quite the opposite, a Democrat and author the RAISE Act, Alex Bores, has become LTF’s prime target to defeat in 2026, Politico reported. LTF plans to invest many millions in ads to block Bores’ Congressional bid, CNBC reported.

New York lawmakers passed the RAISE Act this summer, but it’s still waiting for New York’s Democratic governor, Kathy Hochul, to sign it into law. If that happens—potentially by the end of this year—big tech companies like Google and OpenAI will have to submit risk disclosures and safety assessments or else face fines up to $30 million.

LTF leaders, Zac Moffatt and Josh Vlasto, have accused Bores of “pushing “ideological and politically motivated legislation that would ‘handcuff’ the US and its ability to lead in AI,” Forbes reported. But Bores told Ars that even the tech industry groups spending hundreds of thousands of dollars opposing his law have reported that tech giants would only have to hire one additional person to comply with the law. To him, that shows how “simple” it would be for AI firms to comply with many state laws.

To LTF, whose donors include Marc Andreessen and OpenAI cofounder Greg Brockman, defeating Bores would keep the opposition out of Congress, where it could be easier to meddle with industry dreams that AI won’t be heavily regulated. Scalise argued Tuesday that the AI preemption is necessary to promote an open marketplace, because “AI is where a lot of new massive investment is going” and “we want that money to be invested in America.”

“And when you see some states starting to put a patchwork of limitations, that’s why it’s come to the federal government’s attention to allow for an open marketplace, so you don’t have limitations that hurt innovation,” Scalise said.

Bores told Ars that he agrees that a federal law would be superior to a patchwork of state laws, but AI is moving “too quickly,” and “New York had to take action to protect New Yorkers.”

Why Bores’ bill has GOP so spooked

With a bachelor’s degree in computer science and prior work as an engineer at Palantir, Bores hopes to make it to Congress to help bridge bipartisan gaps and drive innovation in the US. He told Ars that the RAISE Act is not intended to block AI innovation but to “be a first step that deals with the absolute worst possible outcomes” until Congress is done deliberating a federal framework.

Bores emphasized that stakeholders in the tech industry helped shape the RAISE Act, which he described as “a limited bill that is focused on the most extreme risks.”

“I would never be the one to say that once the RAISE Act is signed, we’ve solved the problems of AI,” Bores told Ars. Instead, it’s meant to help states combat risks that can’t be undone, such as bad actors using AI to build “a bioweapon or doing an automated crime spree that results in billions of dollars in damage.” The bill defines “critical harm” as “the death or serious injury of 100 people or at least $1 billion in damages,” setting a seemingly high bar for the types of doomsday scenarios that AI firms would have to plan for.

Bores agrees with Trump-aligned critics who advocate that the US should “regulate just how people use” AI, “not the development of the technology itself.” But he told Ars that Republicans’ efforts to block states from regulating the models themselves are “a silly way to think about risk,” since “there’s certain catastrophic incidents where if you just said, ‘well, we’ll just sue the person afterwards,’ no one would be satisfied by that resolution.”

Whether Hochul will sign the RAISE Act has yet to be seen. Earlier this year, California Governor Gavin Newsom vetoed a similar law that the AI industry worried would rock their bottom lines by requiring a “kill switch” in case AI models went off the rails. Newsom did, however, sign a less extreme measure, the Transparency in Frontier Artificial Intelligence Act. And other states, including Colorado and Illinois, have passed similarly broad AI transparency laws providing consumer and employee protections.

Bores told Ars in mid-November that he’d had informal talks with Hochul about possible changes to the RAISE Act, but she had not yet begun the formal process of proposing amendments. The clock is seemingly ticking, though, as Hochul has to take action on the bill by the end of the year, and once it reaches her desk, she has 10 days to sign it.

Whether Hochul signs the law or not, Bores will likely continue to face opposition over authoring the bill, as he runs to represent New York’s 12th Congressional District in 2026. With a history of passing bipartisan bills in his state, he’s hoping to be elected so he can work with lawmakers across the aisle to pass other far-reaching tech regulations.

Meanwhile, Trump may face pressure to delay an executive order requiring AI preemption, Forbes reported, as “AI’s economic impact and labor displacement” are “rising as voter concerns” ahead of the midterm elections. Public First, a bipartisan initiative aligned with ARI, has said that 97 percent of Americans want AI safety rules, Forbes reported.

Like Bores, ARI plans to keep pushing a bipartisan movement that could scramble Republicans from ever unifying behind Trump’s message that state AI laws risk throttling US innovation and endangering national security, should a less-regulated AI industry in China race ahead.

To maintain momentum, ARI created a tracker showing opposition to federal preemption of state AI laws. Among recent commenters logged was Andrew Gounardes, a Democrat and state senator in New York—where Bores noted a poll found that 84 percent of residents supported the RAISE Act, only 8 percent opposed, and 8 percent were undecided. Gounardes joined critics on the far right, like Steve Bannon, who warned that federal preemption was a big gift for Big Tech. AI firms and the venture capitalist lobbyists “don’t want any regulation whatsoever,” Gounardes argued.

“They say they support a national standard, but in reality, it’s just cheaper for them to buy off Congress to do nothing than it is to try and buy off 50 state legislatures,” Gounardes said.

Bores expects that his experience in the tech industry could help Congress avoid that fate while his policies like the RAISE Act could sway voters who “don’t want Trump mega-donors writing all tech policy,” he wrote on X.

“I am someone with a master’s in computer science, two patents, and nearly a decade working in tech,” Bores told CNBC. “If they are scared of people who understand their business regulating their business, they are telling on themselves.”

Photo of Ashley Belanger

Ashley is a senior policy reporter for Ars Technica, dedicated to tracking social impacts of emerging policies and new technologies. She is a Chicago-based journalist with 20 years of experience.

Republicans drop Trump-ordered block on state AI laws from defense bill Read More »

meet-cdc’s-new-lead-vaccine-advisor-who-thinks-shots-cause-heart-disease

Meet CDC’s new lead vaccine advisor who thinks shots cause heart disease


Milhoan has a history of touting unproven COVID cures while disparaging vaccines.

Kirk Milhoan, James Pagano, and Robert Malone are seen during a meeting of the CDC’s Advisory Committee on Immunization Practices on September 18, 2025 in Chamblee, Georgia. Credit: Getty | Elijah Nouvelage

When the federal vaccine committee hand-picked by anti-vaccine Health Secretary Robert F. Kennedy Jr. meets again this week, it will have yet another new chairperson to lead its ongoing work of dismantling the evidence-based vaccine recommendations set by the Centers for Disease Control and Prevention.

On Monday, the Department of Health and Human Services announced that the chairperson who has been in place since June—when Kennedy fired all 17 expert advisors on the committee and replaced them with questionably qualified allies—is moving to a senior role in the department. Biostatistician Martin Kulldorff will now be the chief science officer for the Office of the Assistant Secretary for Planning and Evaluation (ASPE), HHS said. As such, he’s stepping down from the vaccine committee, the Advisory Committee on Immunization Practices (ACIP).

Kulldorff gained prominence amid the COVID-19 pandemic, criticizing public health responses to the crisis, particularly lockdowns and COVID-19 vaccines. He was a co-author of the Great Barrington Declaration that advocated for letting the deadly virus spread unchecked through the population, which was called unethical by health experts.

As ACIP chair, Kulldorff frequently made false and misleading statements about vaccine safety and efficacy that were in line with Kennedy’s views and statements. While Kulldorff presided over the committee, it made a series of decisions that were sharply denounced by scientific and medical groups as being based on ideology rather than evidence. Those include voting for the removal of the vaccine preservative thimerosal from some flu vaccines, despite well-established data indicating it is safe, with no evidence of harms. The committee also added restrictions to a combination measles, mumps, rubella, and varicella (chickenpox) MMRV vaccine and made an unprecedented effort to prevent Americans from getting COVID-19 vaccines, though the moves were largely ineffective.

In his new role, Kulldorff will be working with ASPE to provide analyses on health policy options, coordinate research efforts, and provide policy advice.

“It’s an honor to join the team of distinguished scientists that Secretary Kennedy has assembled,” Kulldorff said in a press release announcing his new role. “I look forward to contributing to the science-based public health policies that will Make America Healthy Again.”

The new chair, Kirk Milhoan

With Kulldorff moving on, ACIP will now be chaired by Kirk Milhoan, a pediatric oncologist with a track record for spreading COVID-19 misinformation and anti-vaccine views. In August 2021, the Hawaii Medical Board filed a complaint against Milhoan after he appeared on a panel promoting ineffective COVID-19 treatments, downplaying the severity of the disease, and spreading misinformation about COVID-19 vaccines, according to the Maui News. The complaint was dropped in April 2022 after state regulators said they had insufficient evidence to prove a violation of statutes regarding the practice of medicine.

While Milhoan claimed at the time that he is “pro-vaccine,” his statement, affiliations, and prescribing practices suggest otherwise. Milhoan is a member of the Independent Medical Alliance (formerly the Front Line COVID-19 Critical Care Alliance), a group of dubious health care providers set up amid the pandemic to promote the use of the anti-malaria drug hydroxychloroquine and the de-worming drug ivermectin to treat COVID-19. Both drugs have shown to be ineffective and potentially harmful when used to treat or prevent COVID-19.  The IMA also emphasizes vaccine injuries while pushing vitamins and other unproven treatments.

In 2024, Milhoan appeared on a panel set up by Rep. Marjorie Taylor Greene (R-Ga.) to discuss alleged injuries from COVID-19 vaccines alongside other prominent anti-vaccine and COVID-19 misinformation voices. In his opening statement, Milhoan suggested that COVID-19 vaccines were causing severe cardiovascular disease and death in people aged 15 to 44—an unsubstantiated claim he frequently echoes. In his bio for the IMA, he touts that he offers treatment for “vaccine-related cardiovascular toxicity due to the spike protein.”

CDC data has found that boys and young men, aged 12 to 24, have a heightened risk of myocarditis (inflammation of the heart) after COVID-19 vaccination. However, the cases are rare, relatively mild, and almost always resolve, according to CDC data. In a COVID-19 safety data presentation in June, CDC staff scientists reported that its vast vaccine safety monitoring systems indicated that in males 12–24, there are 27 myocarditis cases per million doses of COVID-19 vaccine administered (roughly one case in 37,000 doses). In cases identified during 2021, 83 percent recovered within three months, with more than 90 percent recovering within the year. The monitoring data found no instances of cardiac transplant or death from COVID-19 vaccination.

While anti-vaccine activists have seized on this minor risk from vaccination, health experts note that the risk of myocarditis and other inflammatory conditions from a COVID-19 infection is significantly greater than the risk from vaccination. Exact estimates vary, but one CDC study in 2021 found that people with COVID-19 infections had a 16-fold higher risk of myocarditis than people without the infection. Specifically, the study estimated that there were 150 myocarditis cases among 100,000 COVID-19-infected patients versus just nine myocarditis cases among 100,000 people without COVID-19 infections and who were also unvaccinated. Similar to what’s seen with vaccination, the study found that young males were most at risk of myocarditis.

Kennedy’s allies attack on COVID-19 shots

Kennedy and his allies, like Milhoan, have consistently inflated the risk of myocarditis from COVID-19 vaccination, with some claiming without evidence that they have caused sudden cardiac arrest and deaths in young males, though studies have found no such link. In 2022, Milhoan and fellow ACIP member and conspiracy theorist Robert Malone were featured in a viral social media post suggesting that 50 percent of college athletes in the Big Ten athletic conference had myocarditis linked to COVID-19 vaccines, which could lead to deaths if they played. But the two were referencing a JAMA Cardiology study that examined subclinical myocarditis in Big Ten athletes after COVID-19 infection—not vaccination. In fact, researchers confirmed for an AFP fact check that none of the athletes in the study were vaccinated. And the rate of subclinical myocarditis in the group was 2.3 percent, not 50 percent.

Milhoan’s misinformation about the cardiovascular harms from COVID-19 vaccines seems particularly pertinent to the direction of Kennedy’s anti-vaccine allies. On Friday, Vinay Prasad, the Food and Drug Administration’s top vaccine regulator, sent a memo to staff claiming without evidence that COVID-19 vaccines have killed 10 children. The memo provides little information about the extraordinary claim, but it hints that the deaths were linked to myocarditis and found among reports submitted between 2021 and 2024 to the CDC’s Vaccine Adverse Event Reporting System (VAERS).

VAERS is a system by which anyone, including members of the public, can report anything they think could be linked to vaccines. The reports are considered a type of early warning system, but the vast majority of the reports submitted are not actually related to vaccines. Further, CDC scientists have thoroughly evaluated VAERS reports and ruled out deaths attributed to COVID-19 vaccines. Prasad’s memo—which experts have speculated was designed to be leaked to produce alarming headlines about child deaths—claimed that before Trump administration officials with anti-vaccine views began sifting through the data, these deaths were “ignored” by FDA and CDC scientists. Prasad also claimed that there could be many more deaths that have gone unreported, despite the fact that healthcare providers have been legally required to report any deaths that occurred after COVID-19 vaccination, regardless of cause.

This week’s ACIP meeting

In this week’s scheduled ACIP meeting on Thursday and Friday, COVID-19 vaccines don’t appear on the draft agenda. Instead, ACIP is expected to vote to remove a recommendation for a birth dose of the hepatitis B vaccine. That dose protects newborns from contracting the highly infectious virus from their mothers during birth or from other family or acquaintances shortly after birth. About half of the people infected with hepatitis B are not aware of their infections, and testing of mothers before birth is imperfect. That can leave newborns particularly vulnerable, as infections that start at or shortly after birth almost always develop into chronic infections that can lead to liver disease, liver transplant, and cancer. In a previous ACIP meeting, CDC staff scientists presented data showing that there are no significant harms of birth doses and there is no evidence that delaying the immunization offers any benefit.

The committee is also taking on the childhood vaccine schedule as a whole, though the agenda on this topic is not yet clear. In his memo, Prasad attacked the common practice of providing multiple vaccinations at once, hinting that it could be a way in which the committee will try to dismantle current childhood vaccination recommendations. On Tuesday, The Washington Post reported that the committee will examine whether the childhood vaccine schedule as a whole is causing allergies and autoimmune diseases, something Kennedy and his anti-vaccine organization have long floated despite evidence refuting a link.

Under clear attack are aluminum salt adjuvants, which are used in many vaccines to help spur protective immune responses. Aluminum salts have been used safely in vaccines for more than 70 years. The FDA notes that the most common source of aluminum exposure is from food and water, not vaccines.

Photo of Beth Mole

Beth is Ars Technica’s Senior Health Reporter. Beth has a Ph.D. in microbiology from the University of North Carolina at Chapel Hill and attended the Science Communication program at the University of California, Santa Cruz. She specializes in covering infectious diseases, public health, and microbes.

Meet CDC’s new lead vaccine advisor who thinks shots cause heart disease Read More »

samsung-reveals-galaxy-z-trifold-with-10-inch-foldable-screen,-astronomical-price

Samsung reveals Galaxy Z TriFold with 10-inch foldable screen, astronomical price

Samsung has a new foldable smartphone, and it’s not just another Z Flip or Z Fold. The Galaxy Z TriFold has three articulating sections that house a massive 10-inch tablet-style screen, along with a traditional smartphone screen on the outside. The lavish new smartphone is launching this month in South Korea with a hefty price tag, and it will eventually make its way to the US in early 2026.

Samsung says it refined its Armor FlexHinge design for the TriFold. The device’s two hinges are slightly different sizes because the phone’s three panels have distinct shapes. The center panel is the thickest at 4.2 mm, and the other two are fractions of a millimeter thinner. The phone has apparently been designed to account for the varying sizes and weights, allowing the frame to fold up tight in a pocketable form factor.

Huawei’s impressive Mate XT tri-fold phones have been making the rounds online, but they’re not available in Western markets. Samsung’s new foldable looks similar at a glance, but the way the three panels fit together is different. The Mate XT folds in a Z-shaped configuration, using part of the main screen as the cover display. On Samsung’s phone, the left and right segments fold inward behind the separate cover screen. Samsung claims it has tested the design extensively to verify that the hinges will hold up to daily use for years.

Precision Engineering in Every Fold | Galaxy Z TriFold

While this does push the definition of “pocketable” for some people, the Galaxy Z TriFold is a tablet that technically fits in your pocket. When folded, it measures 12.9 mm thick, which is much more unwieldy than the Galaxy Z Fold 7‘s 8.9 mm profile. However, the TriFold is only a little thicker than Samsung’s older tablet-style foldables like the Galaxy Z Fold 6. The 1080p cover screen measures 6.5 inches, which is also quite similar to the Z Fold 7. It is very, very heavy for a phone, though, tipping the scales at 309 g.

Samsung reveals Galaxy Z TriFold with 10-inch foldable screen, astronomical price Read More »

3d-model-shows-small-clans-created-easter-island-statues

3D model shows small clans created Easter Island statues

Credit: ArcGIS

Easter Island is famous for its giant monumental statues, called moai, built some 800 years ago. The volcanic rock used for the moai came from a quarry site called Rano Raraku. Archaeologists have created a high-resolution interactive 3D model of the quarry site to learn more about the processes used to create the moai. (You can explore the full interactive model here.) According to a paper published in the journal PLoS ONE, the model shows that there were numerous independent groups, probably family clans, that created the moai, rather than a centralized management system.

“You can see things that you couldn’t actually see on the ground. You can see tops and sides and all kinds of areas that just would never be able to walk to,” said co-author Carl Lipo of Binghamton University. “We can say, ‘Here, go look at it.’ If you want to see the different kinds of carving, fly around and see stuff there. We’re documenting something that really has needed to be documented, but in a way that’s really comprehensive and shareable.”

Lipo is one of the foremost experts on the Easter Island moai. In October, we reported on Lipo’s experimental confirmation—based on 3D modeling of the physics and new field tests to re-create that motion—that Easter Island’s people transported the statues in a vertical position, with workers using ropes to essentially “walk” the moai onto their platforms. To explain the presence of so many moai, the assumption has been that the island was once home to tens of thousands of people.

Lipo’s latest field trials showed that the “walking” method can be accomplished with far fewer workers: 18 people, four on each lateral rope and 10 on a rear rope, to achieve the side-to-side walking motion. They were efficient enough in coordinating their efforts to move the statue forward 100 meters in just 40 minutes. That’s because the method operates on basic pendulum dynamics, which minimizes friction between the base and the ground. It’s also a technique that exploits the gradual build-up of amplitude, suggesting a sophisticated understanding of resonance principles.

3D model shows small clans created Easter Island statues Read More »

the-missile-meant-to-strike-fear-in-russia’s-enemies-fails-once-again

The missile meant to strike fear in Russia’s enemies fails once again

Therefore, it’s no wonder Russian officials like to talk up Sarmat’s capabilities. Russian President Vladimir Putin has called Sarmat a “truly unique weapon” that will “provide food for thought for those who, in the heat of frenzied aggressive rhetoric, try to threaten our country.” Dmitry Rogozin, then the head of Russia’s space agency, called the Sarmat missile a “superweapon” after its first test flight in 2022.

So far, what’s unique about the Sarmat missile is its propensity for failure. The missile’s first full-scale test flight in 2022 apparently went well, but the program has suffered a string of consecutive failures since then, most notably a catastrophic explosion last year that destroyed the Sarmat missile’s underground silo in northern Russia.

The Sarmat is supposed to replace Russia’s aging R-36M2 strategic ICBM fleet, which was built in Ukraine. The RS-28, sometimes called the Satan II, is a “product solely of Russian industry cooperation,” according to Russia’s Ministry of Defense.

The video of the missile failure last week lacks the resolution to confirm whether it was a Sarmat missile or the older-model R-36M2, analysts agree it was most likely a Sarmat. The missile silo used for Friday’s test was recently renovated, perhaps to convert it to support Sarmat tests after the destruction of the new missile’s northern launch site last year.

“Work there began in Spring 2025, after the ice thawed,” wrote Etienne Marcuz, an analyst on strategic armaments at the Foundation for Strategic Research, a French think tank. The “urgent renovation” of the missile silo at Dombarovsky lends support for the hypothesis that last week’s accident involved the Sarmat, and not the R-36M2, which was last tested more than 10 years ago, Marcuz wrote on X.

“If this is indeed another Sarmat failure, it would be highly detrimental to the medium-term future of Russian deterrence,” Marcuz continued. “The aging R-36M2 missiles, which carry a significant portion of Russia’s strategic warheads, are seeing their replacement pushed even further into the future, while their maintenance—previously handled by Ukraine until 2014—remains highly uncertain.”

In this pool photograph distributed by the Russian state media agency Sputnik, Russia’s President Vladimir Putin chairs a Security Council meeting at the Kremlin in Moscow on November 5, 2025. Credit: Gavriil Grigorov/Pool/AFP via Getty Images

Podvig, the UN researcher who also runs the Russian Nuclear Forces blog site, agrees with Marcuz’s conclusions. With the R-36M2 missile soon to retire, “it is extremely unlikely that the Rocket Forces would want to test launch them,” Podvig wrote on his website. “This leaves Sarmat.”

The failure adds fresh uncertainty to the readiness of Russia’s nuclear arsenal. If this were actually a test of one of Russia’s older ICBMs, the result would raise questions about hardware decay and obsolescence. In the more likely case of a Sarmat test flight, it would be the latest in a series of problems that have delayed its entry into service since 2018.

The missile meant to strike fear in Russia’s enemies fails once again Read More »

openai-desperate-to-avoid-explaining-why-it-deleted-pirated-book-datasets

OpenAI desperate to avoid explaining why it deleted pirated book datasets


Not for OpenAI to reason why?

OpenAI risks increased fines after deleting pirated books datasets.

OpenAI may soon be forced to explain why it deleted a pair of controversial datasets composed of pirated books, and the stakes could not be higher.

At the heart of a class-action lawsuit from authors alleging that ChatGPT was illegally trained on their works, OpenAI’s decision to delete the datasets could end up being a deciding factor that gives the authors the win.

It’s undisputed that OpenAI deleted the datasets, known as “Books 1” and “Books 2,” prior to ChatGPT’s release in 2022. Created by former OpenAI employees in 2021, the datasets were built by scraping the open web and seizing the bulk of its data from a shadow library called Library Genesis (LibGen).

As OpenAI tells it, the datasets fell out of use within that same year, prompting an internal decision to delete them.

But the authors suspect there’s more to the story than that. They noted that OpenAI appeared to flip-flop by retracting its claim that the datasets’ “non-use” was a reason for deletion, then later claiming that all reasons for deletion, including “non-use,” should be shielded under attorney-client privilege.

To the authors, it seemed like OpenAI was quickly backtracking after the court granted the authors’ discovery requests to review OpenAI’s internal messages on the firm’s “non-use.”

In fact, OpenAI’s reversal only made authors more eager to see how OpenAI discussed “non-use,” and now they may get to find out all the reasons why OpenAI deleted the datasets.

Last week, US district judge Ona Wang ordered OpenAI to share all communications with in-house lawyers about deleting the datasets, as well as “all internal references to LibGen that OpenAI has redacted or withheld on the basis of attorney-client privilege.”

According to Wang, OpenAI slipped up by arguing that “non-use” was not a “reason” for deleting the datasets, while simultaneously claiming that it should also be deemed a “reason” considered privileged.

Either way, the judge ruled that OpenAI couldn’t block discovery on “non-use” just by deleting a few words from prior filings that had been on the docket for more than a year.

“OpenAI has gone back-and-forth on whether ‘non-use’ as a ‘reason’ for the deletion of Books1 and Books2 is privileged at all,” Wang wrote. “OpenAI cannot state a ‘reason’ (which implies it is not privileged) and then later assert that the ‘reason’ is privileged to avoid discovery.”

Additionally, OpenAI’s claim that all reasons for deleting the datasets are privileged “strains credulity,” she concluded, ordering OpenAI to produce a wide range of potentially revealing internal messages by December 8. OpenAI must also make its in-house lawyers available for deposition by December 19.

OpenAI has argued that it never flip-flopped or retracted anything. It simply used vague phrasing that led to confusion over whether any of the reasons for deleting the datasets were considered non-privileged. But Wang didn’t buy into that, concluding that “even if a ‘reason’ like ‘non-use’ could be privileged, OpenAI has waived privilege by making a moving target of its privilege assertions.”

Asked for comment, OpenAI told Ars that “we disagree with the ruling and intend to appeal.”

OpenAI’s “flip-flop” may cost it the win

So far, OpenAI has avoided disclosing its rationale, claiming that all the reasons it had for deleting the datasets are privileged. In-house lawyers weighed in on the decision to delete and were even copied on a Slack channel initially called “excise-libgen.”

But Wang reviewed those Slack messages and found that “the vast majority of these communications were not privileged because they were ‘plainly devoid of any request for legal advice and counsel [did] not once weigh in.’”

In a particularly non-privileged batch of messages, one OpenAI lawyer, Jason Kwon, only weighed in once, the judge noted, to recommend the channel name be changed to “project-clear.” Wang reminded OpenAI that “the entirety of the Slack channel and all messages contained therein is not privileged simply because it was created at the direction of an attorney and/or the fact that a lawyer was copied on the communications.”

The authors believe that exposing OpenAI’s rationale may help prove that the ChatGPT maker willfully infringed on copyrights when pirating the book data. As Wang explained, OpenAI’s retraction risked putting the AI firm’s “good faith and state of mind at issue,” which could increase fines in a loss.

“In a copyright case, a court can increase the award of statutory damages up to $150,000 per infringed work if the infringement was willful, meaning the defendant ‘was actually aware of the infringing activity’ or the ‘defendant’s actions were the result of reckless disregard for, or willful blindness to, the copyright holder’s rights,’” Wang wrote.

In a court transcript, a lawyer representing some of the authors suing OpenAI, Christopher Young, noted that OpenAI could be in trouble if evidence showed that it decided against using the datasets for later models due to legal risks. He also suggested that OpenAI could be using the datasets under different names to mask further infringement.

Judge calls out OpenAI for twisting fair use ruling

Wang also found it contradictory that OpenAI continued to argue in a recent filing that it acted in good faith, while “artfully” removing “its good faith affirmative defense and key words such as ‘innocent,’ ‘reasonably believed,’ and ‘good faith.’” These changes only strengthened discovery requests to explore authors’ willfulness theory, Wang wrote, noting the sought-after internal messages would now be critical for the court’s review.

“A jury is entitled to know the basis for OpenAI’s purported good faith,” Wang wrote.

The judge appeared particularly frustrated by OpenAI seemingly twisting the Anthropic ruling to defend against the authors’ request to learn more about the deletion of the datasets.

In a footnote, Wang called out OpenAI for “bizarrely” citing an Anthropic ruling that “grossly” misrepresented Judge William Alsup’s decision by claiming that he found that “downloading pirated copies of books is lawful as long as they are subsequently used for training an LLM.”

Instead, Alsup wrote that he doubted that “any accused infringer could ever meet its burden of explaining why downloading source copies from pirate sites that it could have purchased or otherwise accessed lawfully was itself reasonably necessary to any subsequent fair use.”

If anything, Wang wrote, OpenAI’s decision to pirate book data—then delete it—seemed “to fall squarely into the category of activities proscribed by” Alsup. For emphasis, she quoted Alsup’s order, which said, “such piracy of otherwise available copies is inherently, irredeemably infringing even if the pirated copies are immediately used for the transformative use and immediately discarded.”

For the authors, getting hold of OpenAI’s privileged communications could tip the scales in their favor, the Hollywood Reporter suggested. Some authors believe the key to winning could be testimony from Anthropic CEO Dario Amodei, who is accused of creating the controversial datasets while he was still at OpenAI. The authors think Amodei also possesses information on the destruction of the datasets, court filings show.

OpenAI tried to fight the authors’ motion to depose Amodei, but a judge sided with the authors in March, compelling Amodei to answer their biggest questions on his involvement.

Whether Amodei’s testimony is a bombshell remains to be seen, but it’s clear that OpenAI may struggle to overcome claims of willful infringement. Wang noted there is a “fundamental conflict” in circumstances “where a party asserts a good faith defense based on advice of counsel but then blocks inquiry into their state of mind by asserting attorney-client privilege,” suggesting that OpenAI may have substantially weakened its defense.

The outcome of the dispute over the deletions could influence OpenAI’s calculus on whether it should ultimately settle the lawsuit. Ahead of the Anthropic settlement—the largest publicly reported copyright class action settlement in history—authors suing pointed to evidence that Anthropic became “not so gung ho about” training on pirated books “for legal reasons.” That seems to be the type of smoking-gun evidence that authors hope will emerge from OpenAI’s withheld Slack messages.

Photo of Ashley Belanger

Ashley is a senior policy reporter for Ars Technica, dedicated to tracking social impacts of emerging policies and new technologies. She is a Chicago-based journalist with 20 years of experience.

OpenAI desperate to avoid explaining why it deleted pirated book datasets Read More »

space-ceo-explains-why-he-believes-private-space-stations-are-a-viable-business

Space CEO explains why he believes private space stations are a viable business

It’s a critical time for companies competing to develop a commercial successor to the International Space Station. NASA is working with several companies, including Axiom Space, Voyager Technologies, Blue Origin, and Vast, to develop concepts for private stations where it can lease time for its astronauts.

The space agency awarded Phase One contracts several years ago and is now in the final stages of writing requirements for Phase Two after asking for feedback from industry partners in September. This program is known as Commercial LEO Destinations, or CLDs in industry parlance.

Time is running out for NASA if it wants to establish continuity from the International Space Station, which will reach its end of life in 2030, with a follow-on station ready to go before then.

One of the more intriguing companies in the competition is Voyager Technologies, which recently announced a strategic investment from Janus Henderson, a global investment firm. In another sign that the competition is heating up, Voyager also just hired John Baum away from Vast, where he was the company’s business development leader.

To get a sense of this competition and how Voyager is coming along with its Starlab space station project, Ars spoke with the firm’s chairman, Dylan Taylor. This conversation has been lightly edited for clarity.

Ars: I know a lot of the companies working on CLDs are actively fundraising right now. How is this coming along for Voyager and Starlab?

Dylan Taylor: Fundraising is going quite well. You saw the Janus announcement. That’s significant for a few reasons. One is, it’s a significant investment. Of course, we’re not disclosing exactly how much. (Editor’s note: It likely is on the order of $100 million.) But the more positive development on the Janus investment is that they are such a well-known, well-respected financial investor.

If you look at the kind of bellwether investors, Janus would be up there with a Blackstone or Blackrock or Fidelity. So it’s significant not only in terms of capital contribution, but in… showing that commercial space stations are investable. This isn’t money coming from the Gulf States. It’s not a syndication of a bunch of $1,000 checks from retail investors. This is a very significant institutional investor coming in, and it’s a signal to the market. They did significant diligence on all our competitors, and they went out of the way saying that we’re far and away the best business plan, best design, and everything else, so that’s why it’s so meaningful.

Space CEO explains why he believes private space stations are a viable business Read More »

ula-aimed-to-launch-up-to-10-vulcan-rockets-this-year—it-will-fly-just-once

ULA aimed to launch up to 10 Vulcan rockets this year—it will fly just once

Engineers traced the problem to a manufacturing defect in an insulator on the solid rocket motor, and telemetry data from all four boosters on the following flight in August exhibited “spot-on” performance, according to Bruno. But officials decided to recover the spent expendable motor casings from the Atlantic Ocean for inspections to confirm there were no other surprises or close calls.

The hangup delaying the next Vulcan launches isn’t in rocket production. ULA has hardware for multiple Vulcan rockets in storage at Cape Canaveral Space Force Station, Florida.

Instead, one key reason for Vulcan’s past delays has been the rocket’s performance, particularly its solid rocket boosters. It isn’t clear whether the latest delays are related to the readiness of the Space Force’s GSSAP satellites (the next GPS satellite to fly on Vulcan has been available for launch since 2022), the inspections of Vulcan’s solid rocket motors, or something else.

Vulcan booster cores in storage at Cape Canaveral Space Force Station, Florida. Credit: United Launch Alliance

A Space Systems Command spokesperson told Ars that “appropriate actions are being executed to ensure a successful USSF-87 mission … The teams analyze all hardware as well as available data from previous missions to evaluate space flight worthiness of future missions.”

The spokesperson did not provide a specific answer to a question from Ars about inspections on the solid rocket motors from the most recent Vulcan flight.

ULA’s outfitting of a new rocket assembly hangar and a second mobile launch platform for the Vulcan rocket at Cape Canaveral has also seen delays. With so many launches in its backlog, ULA needs capacity to stack and prepare at least two rockets in different buildings at the same time. Eventually, the company’s goal is to launch at an average clip of twice per month.

On Monday, ground crews at Cape Canaveral moved the second Vulcan launch platform to the company’s launch pad for fit checks and “initial technical testing.” This is a good sign that the company is moving closer to ramping up the Vulcan launch cadence, but it’s now clear it won’t happen this year.

Vulcan’s slow launch rate since its first flight in January 2024 is not unusual for new rockets. It took 28 months for SpaceX’s Falcon 9 and ULA’s Atlas V to reach their fourth flight, a timeline that the Vulcan vehicle will reach in May 2026.

The Delta IV rocket from ULA flew its fourth mission 25 months after debuting in 2002. Europe’s Ariane 6 rocket reached its fourth flight in 16 months, but it shares more in common with its predecessor than the others. SpaceX’s Starship also had a faster ramp-up, with its fourth test flight coming less than 14 months after the first.

ULA aimed to launch up to 10 Vulcan rockets this year—it will fly just once Read More »

russia’s-soyuz-5-will-soon-come-alive.-but-will-anyone-want-to-fly-on-it?

Russia’s Soyuz 5 will soon come alive. But will anyone want to fly on it?

The Soyuz 5 rocket, also named Irtysh for a river that flows through Russia and Kazakhstan, answers to that purpose. Its first stage is powered by a single RD-171MV engine, which at sea level has three times the thrust of a single Raptor 3 engine, and is part of a family of engines that are the most powerful liquid-fueled rocket engines in the world. The RD-171MV uses only Russian components.

Russian officials also plan to use the Soyuz 5 rocket as the “boost” stage of a super-heavy lift rocket, known as Yenisei, that would be used for a human lunar program. However the Yenisei rocket seems to be one of those Russian space initiatives that is forever mired in a nebulous development stage—often talked about as a national priority, but rarely advanced.

What market is there?

But the Soyuz 5 rocket now is very real, and it should launch within the next month. The question is, what market will it serve? Russia presently has the Soyuz 2, which has about half the lift capacity, for crew and cargo missions to the International Space Station, as well as the launch of smaller spacecraft. There is also the line of Angara rockets that has come online during the last decade.

The Soyuz 5 slots in between the Soyuz 2 and Angara A5 rocket in terms of performance. So what demand is there for a rocket with 18 tons of capacity to low-Earth orbit? One concern is that the number of geostationary satellites launched annually, once the bread and butter of the Proton vehicle, has dropped precipitously.

Another is Russia’s invasion of Ukraine, which has taken Russian rockets off the table for many Western satellite operators. At the same time, international competition in the medium-lift market has stiffened. China has an increasing number of government and commercial options, and India’s launch offerings are growing as well. And for any company or country mostly concerned about price, Russia almost certainly can’t beat the reusable Falcon 9 booster offered by SpaceX.

Russia’s Soyuz 5 will soon come alive. But will anyone want to fly on it? Read More »